Medopad completes $25 million B round of financing
-
Last Update: 2021-03-02
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Nov. 6 (Xinhua) -- Mobile healthcare company Medopad announced the completion of a $25 million round of B financing. The round of funding is led by pharmaceutical giant Bayer, NWS Holdings and Healthbox.After this round of financing, Medopad's market value will exceed $200 million. In addition, Bayer will work with Medopad to develop digital biomarker diagnostics to improve human heart health.Since its establishment, Medopad has completed three financings with a total investment of US$54 million. The company completed a $1 million seed round in January 2016 and a $28 million A round in February 2018.Founded in 2008 and headquartered in London, UK, Medopad is a global mobile healthcare company with offices in the US and China. The company is committed to developing advanced diagnostic technologies to improve the quality of life of patients with chronic, rare and complex diseases. Medopad works with the world's leading healthcare, pharmaceutical and technology companies to create a connected digital healthcare ecosystem. (Arterial mesh)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
